Intervention not reported
Prebiotics/Probiotics/Synbiotics(14 trials; 649 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Prebiotics/Probiotics/Synbiotics(5 trials; 243 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether the intervention changes prebiotics/Probiotics/Synbiotics(5 trials; 243 participants) (very low certainty).
1 finding from 1 review
OR 0.67 [0.3, 1.46]
Studies not reported
Very low
Intervention not reported
Prebiotics/Probiotics/Synbiotics(15 trials; 763 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Prebiotics/Probiotics/Synbiotics(6 trials; 318 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Prebiotics/Probiotics/Synbiotics(6 trials; 296 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Prebiotics/Probiotics/Synbiotics(5 trials; 289 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Selective bowel decontamination versus prebiotics with probiotics · people undergoing liver transplantation
2 findings from 1 review
Prebiotics with probiotics versus prebiotics · people undergoing liver transplantation
2 findings from 1 review
Mortality ‐ Prebiotics and probiotics versus none · patients undergoing liver resections
1 finding from 1 review
Mortality ‐ Pre‐operative and post‐operative prebiotics and probiotics versus post‐operative prebiotics and probiotics · patients undergoing liver resections
1 finding from 1 review
Intervention not reported
All‐cause mortality ( · people with hepatic encephalopathy
The intervention showed no clear difference in all‐cause mortality ( (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Change of/or withdrawal from treatment ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes adverse events ‐ Change of/or withdrawal from treatment ( (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
Plasma ammonia concentration (final and change scores) (μmol/L) ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
No‐recovery (incomplete resolution of clinical symptoms) ( · people with hepatic encephalopathy
The intervention probably leads to lower no‐recovery (incomplete resolution of clinical symptoms) ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Overt hepatic encephalopathy ( · people with hepatic encephalopathy
The intervention may leads to lower adverse events ‐ Overt hepatic encephalopathy ( (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Change of/or withdrawal from treatment ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes adverse events ‐ Change of/or withdrawal from treatment ( (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
Plasma ammonia concentration (final and change scores) (μmol/L) ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
All‐cause mortality ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes all‐cause mortality ( (very low certainty).
1 finding from 1 review